Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Black Diamond Therapeutics, Inc. (BDTX) had Consolidated Net Income/Loss of $22.37M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$70.00M |
|
$22.37M |
|
-- |
|
$70.00M |
|
$57.48M |
|
$12.52M |
|
$9.85M |
|
$22.37M |
|
$22.37M |
|
$22.37M |
|
$22.37M |
|
|
Consolidated Net Income/Loss |
$22.37M |
$22.37M |
|
$12.52M |
|
$12.85M |
|
56.87M |
|
57.56M |
|
$0.39 |
|
$0.39 |
|
| Balance Sheet Financials | |
$132.44M |
|
$0.36M |
|
$10.57M |
|
$143.01M |
|
$15.73M |
|
-- |
|
$15.07M |
|
$30.80M |
|
$112.21M |
|
$112.21M |
|
$112.21M |
|
57.14M |
|
| Cash Flow Statement Financials | |
$29.61M |
|
$-44.91M |
|
$-0.15M |
|
$37.26M |
|
$21.82M |
|
$-15.44M |
|
$6.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
17.89% |
|
17.89% |
|
18.35% |
|
31.95% |
|
31.95% |
|
$29.64M |
|
-- |
|
-- |
|
-- |
|
0.49 |
|
-- |
|
-- |
|
-- |
|
19.93% |
|
19.93% |
|
15.64% |
|
19.93% |
|
$1.96 |
|
$0.51 |
|
$0.51 |
|